Immortagen Inc., based in Iowa City, a cancer diagnostics company that develops cloud-based precision medicine using a proprietary software platform, received a $100,000 loan from the Demonstration Fund for proof of concept work and key personnel.

Market: Cancer Genome Sequencing

Immortagen seeks to personalize cancer treatment through private tumor banking, full spectrum genetic profiling, revolutionary Clinical Decision Support algorithms, and advanced mouse models for drug research and development.